Working… Menu

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (CheckMate 568)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02659059
Recruitment Status : Active, not recruiting
First Posted : January 20, 2016
Last Update Posted : August 20, 2020
Information provided by (Responsible Party):
Bristol-Myers Squibb